Porphyria Cutanea Tarda as a Sclerosing Mimic and the First Positive Phase 3 Trial for Dermatomyositis

Conclusions

• The presentation concludes that porphyria cutanea tarda can masquerade as a sclerosing connective tissue disease, sometimes presenting with alopecia porphyrinica and skin sclerosis even without classic blistering or photosensitivity.
• A key diagnostic lesson is that suspected sclerodermoid scalp disease should prompt porphyrin testing, because biopsy alone may misleadingly suggest morphea or scleroderma.
• The speaker emphasizes that true systemic sclerosis can often be ruled in or out clinically from hand findings, nailfold changes, and Raynaud’s rather than extensive testing alone.
• The Phase 3 VALOR trial suggests brepocitinib is a major breakthrough for dermatomyositis because it produced significant improvement across skin, muscle, function, and steroid-sparing outcomes.
• Dual TYK2/JAK1 inhibition appears to suppress the interferon-driven inflammatory pathways central to dermatomyositis, which may explain the drug’s rapid and broad efficacy.
• Brepocitinib showed clinically meaningful skin improvement as early as four weeks, with benefits continuing through 52 weeks and even leading to remission in some patients.
• The trial’s results are notable because they were achieved in a real-world, treatment-refractory dermatomyositis population that included patients with cancer history, interstitial lung disease, and cardiovascular risk factors.
• Overall safety was considered acceptable, with infections more common on brepocitinib but serious complications such as thrombosis or malignancy not increased versus placebo in the study.
• The study supports moving from repeated empiric steroid cycling toward earlier targeted therapy for dermatomyositis.
• The overall message is that porphyria cutanea tarda belongs in the sclerosing differential, and brepocitinib may become the first modern targeted therapy approved for dermatomyositis.